In the same study, they reported that ensartinib at 10 μM could reverse P-gp-mediated resistance to daunorubicin and ABCG2-mediated resistance to mitoxantrone in MDCKII cells transduced with P-gp or ABCG2, and in the human leukemia HL60 cell line overexpressing P-gp or ABCG2. This evidence concerns the gene PGP and leukemia.